Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025
Indigenous peoples and medications for opioid use disorders: A scoping review.
СтатьяScoping ReviewНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gala Natalia, Dobischok Sophia, Bernett Payton, Parker Daniel G, O'Callahan Aidan, Zentner Daysi, Huson Kelsey, Tomaro Jann, Wendt Dennis C
Аннотация
OBJECTIVE: This scoping review was to synthesize the rapidly accelerating literature on Indigenous peoples and medications for opioid use disorder (MOUD) and to identify barriers to implementation and sustainability. The article also addressed outcomes, perspectives, and suggestions for implementing culturally adapted MOUD programs.
METHOD: We conducted a scoping review of articles indexed in MEDLINE, APA PsycInfo, Scopus, and ERIC (through September 2024). Articles needed to include substantive information on an Indigenous population (in Canada, the United States, New Zealand, or Australia), include content on MOUD, and address the intersection of MOUD and Indigenous populations. Titles/abstracts were screened by two reviewers, followed by a full-text review and data extraction.
RESULTS: Forty articles met inclusion criteria, organized under two primary categories: medication type (n = 18) and nonmedication specific (n = 22). Overall, Indigenous clients have a mixed degree of engagement, retention, and positive outcomes within methadone, buprenorphine, and injectable opioid agonist treatment programs. Promising findings emerged for MOUD programs targeting Indigenous youth and that incorporate comprehensive cultural and health frameworks. Across MOUD types, Indigenous clients had consistently lower rates of treatment access and retention than did non-Indigenous clients.
CONCLUSIONS: The findings emphasize the importance of aligning MOUD programs with Indigenous cultural frameworks and involving Indigenous consultation at all stages. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
METHOD: We conducted a scoping review of articles indexed in MEDLINE, APA PsycInfo, Scopus, and ERIC (through September 2024). Articles needed to include substantive information on an Indigenous population (in Canada, the United States, New Zealand, or Australia), include content on MOUD, and address the intersection of MOUD and Indigenous populations. Titles/abstracts were screened by two reviewers, followed by a full-text review and data extraction.
RESULTS: Forty articles met inclusion criteria, organized under two primary categories: medication type (n = 18) and nonmedication specific (n = 22). Overall, Indigenous clients have a mixed degree of engagement, retention, and positive outcomes within methadone, buprenorphine, and injectable opioid agonist treatment programs. Promising findings emerged for MOUD programs targeting Indigenous youth and that incorporate comprehensive cultural and health frameworks. Across MOUD types, Indigenous clients had consistently lower rates of treatment access and retention than did non-Indigenous clients.
CONCLUSIONS: The findings emphasize the importance of aligning MOUD programs with Indigenous cultural frameworks and involving Indigenous consultation at all stages. (PsycInfo Database Record (c) 2025 APA, all rights reserved).